

1 **Machine learning and biological validation identify sphingolipids as key**  
2 **mediators of paclitaxel-induced neuropathy in cancer patients**

3 Jörn Lötsch<sup>1,2a</sup>, Khayal Gasimli<sup>3a</sup>, Sebastian Malkusch<sup>1,2</sup>, Lisa Hahnefeld<sup>1,2</sup>, Carlo Angioni<sup>1</sup>,  
4 Yannick Schreiber<sup>2</sup>, Sandra Trautmann<sup>1,2</sup>, Saskia Wedel<sup>1</sup>, Dominique Thomas<sup>1,2</sup>, Nerea  
5 Ferreiros Bouzas<sup>1,2</sup>, Christian Brandts<sup>4,5</sup>, Benjamin Schnappauf<sup>6</sup>, Christine Solbach<sup>3</sup>, Gerd  
6 Geisslinger<sup>1,2</sup> and Marco Sisignano<sup>1,2\*</sup>

7 <sup>1</sup> Institute of Clinical Pharmacology, Goethe - University, Theodor Stern Kai 7, 60590 Frankfurt  
8 am Main, Germany

9 <sup>2</sup> Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer  
10 Cluster of Excellence for Immune Mediated Diseases CIMD, Theodor-Stern-Kai 7, 60596  
11 Frankfurt am Main, Germany

12 <sup>3</sup> Goethe University, Department of Gynecology and Obstetrics, Theodor-Stern-Kai 7,  
13 Frankfurt/Main, Germany

14 <sup>4</sup> German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ),  
15 Heidelberg, 69120, Germany

16 <sup>5</sup> Goethe University, University Cancer Center Frankfurt (UCT), Goethe University Hospital,  
17 Frankfurt am Main 60590, Germany

18 <sup>6</sup> Oncology Center, Sana-Klinikum Offenbach, Starkenburgring 66, 63069 Offenbach

19 <sup>a</sup> these authors contributed equally

20

21 **Keywords:** paclitaxel, neuropathy, CIPN, sphingolipids, TRV1

22 Correspondence to: Marco Sisignano, PhD, Goethe-University, Theodor - Stern - Kai 7,  
23 60590 Frankfurt am Main, Germany, e-mail: [Marco.Sisignano@med.uni-frankfurt.de](mailto:Marco.Sisignano@med.uni-frankfurt.de), Phone:  
24 +49-69-6301-87819, Fax: +49-69-6301-83378

25

26 The authors have declared that no competing interests exist.

## 27 **Abstract**

28 **Background:** Chemotherapy-induced peripheral neuropathy (CIPN) is a serious therapy-  
29 limiting side effect of commonly used anticancer drugs. Previous studies suggest that lipids  
30 may play a role in CIPN. Therefore, the present study aimed to identify the particular types of  
31 lipids that are regulated as a consequence of paclitaxel administration and may be  
32 associated with the occurrence of post-therapeutic neuropathy.

33 **Methods:** High resolution mass spectrometry lipidomics was applied to quantify  $d = 255$   
34 different lipid mediators in the blood of  $n = 31$  patients drawn before and after paclitaxel  
35 therapy for breast cancer treatment. A variety of supervised statistical and machine-learning  
36 methods was applied to identify lipids that were regulated during paclitaxel therapy or  
37 differed among patients with and without post-therapeutic neuropathy.

38 **Results:** Twenty-seven lipids were identified that carried relevant information to train  
39 machine learning algorithms to identify, in new cases, whether a blood sample was drawn  
40 before or after paclitaxel therapy with a median balanced accuracy of up to 90%. One of the  
41 top hits, sphinganine-1-phosphate (SA1P), was found to induce calcium transients in sensory  
42 neurons via the transient receptor potential vanilloid 1 (TRPV1) channel and sphingosine-1-  
43 phosphate receptors. SA1P also showed different blood concentrations between patients with  
44 and without neuropathy.

45 **Conclusions:** Present findings suggest an important role for sphinganine-1-phosphate in  
46 paclitaxel-induced biological changes associated with neuropathic side effects. The identified  
47 SA1P, through its receptors, provides a potential drug target for co-therapy with paclitaxel to  
48 reduce one of its major and therapy-limiting side effects.

## 49 Introduction

50 Paclitaxel is a standard adjuvant treatment for breast cancer and several other cancers.  
51 Originally isolated from the yew tree *Taxus brevifolia*, it inhibits mitosis by stabilizing  
52 microtubules and preventing tubulin depolymerization (5-7). A serious dose- and therapy-  
53 limiting side effect, which it shares with other commonly used cytostatic drugs, is the  
54 chemotherapy-induced peripheral neuropathy and neuropathic pain (CIPN), which affects up  
55 to 80% of treated patients (1, 2). Currently, there are no pharmacologic treatments for CIPN  
56 expert for duloxetine (1, 3, 4). Therefore, research on the mechanism of paclitaxel induced  
57 CIPN with possible identification of novel treatments is an active research topic.

58 Several genes and neurofilament proteins have been implicated in paclitaxel-induced  
59 neuropathy. More recently, lipid mediators have been shown to be produced at high levels in  
60 sensory neurons, neuronal tissue and immune cells after chemotherapy due to oxidative  
61 stress and have been shown to contribute to chemotherapy-induced neuropathy and  
62 neuropathic pain by modulating neuronal ion channels (11-14). Therefore, they are of  
63 particular interest as signaling molecules and potential markers for chemotherapy-induced  
64 neuropathy in patients. In fact, lipids are already considered markers for other neurological  
65 diseases such as Alzheimer's disease and amyotrophic lateral sclerosis (ALS) (15-17).  
66 However, a systematic approach to investigate lipids in patients with paclitaxel-induced  
67 neuropathy has not been performed.

68 In this prospective clinical cohort study, plasma concentrations of 255 different lipid  
69 mediators were evaluated for changes in their concentrations associated with paclitaxel  
70 treatment. A comprehensive LC-MS/MS-based targeted and LC-QTOFMS-based untargeted  
71 lipidomics screening was performed on plasma samples from paclitaxel-treated patients.  
72 Lipid groups measured included eicosanoids, endocannabinoids, oxidized linoleic acid

73 metabolites, sphingolipids, lysophospholipids and free fatty acids, many of which have been  
74 previously associated with persistent pain states (18-20). A data-driven approach was used  
75 to identify lipid mediators whose concentrations could be used to train machine learning  
76 algorithms to identify, in new cases, whether a plasma sample was collected before or after  
77 therapy, or from a patient with or without post-therapy neuropathy. The biological relevance  
78 of the findings was then validated in vitro by applying SA1P to primary sensory neurons  
79 using calcium imaging.

## 80 **Materials and Methods**

### 81 ***Patients and study design***

82 This was a prospective single-arm study enrolling patients with breast cancer. The study was  
83 conducted in accordance with the Declaration of Helsinki on Biomedical Research Involving  
84 Human Subjects and was approved by the Ethics Committee of the Medical Faculty of the  
85 Goethe-University, Frankfurt am Main, Germany. Informed written consent was obtained  
86 from each of the participants.

87 Sixty patients (one male, 59 female with breast cancer and undergoing paclitaxel treatment  
88 were recruited from the Tumor Center of the University Hospital Frankfurt, Germany (UCT).  
89 Most patients (n = 47) received the "paclitaxel-weekly" schedule, consisting of 12 cycles of  
90 paclitaxel treatment (80 mg/m<sup>2</sup>, each week); a few patients (n = 13) received mixed  
91 carboplatin/paclitaxel treatment (Table S1). A blood sample was collected from each patient  
92 before and after chemotherapy, and the degree of neuropathy after chemotherapy was  
93 assessed as described below. Plasma was isolated from the blood samples immediately  
94 after blood collection to ensure lipid stability. Plasma was stored at -80°C until analysis.

95 All patients provided a blood sample before chemotherapy; however, only 36 patients of the  
96 patients provided a second blood sample after chemotherapy. For our analysis, we focused  
97 on patients that had two blood samples. Therefore, 72 samples from 36 patients (before and  
98 after chemotherapy) were analyzed using both LC-MS/MS-based targeted and LC-QTOFMS-  
99 based untargeted lipidomics. A total of 255 individual lipids were detected in each sample.  
100 From the resulting data, five patients had to be excluded due to incomplete lipidomics data  
101 (more than 20% of the analytes could not be detected). The remaining 62 samples from 31  
102 patients were used for the machine learning analysis (Figure 1).

### 103 ***Assessment of neuropathy***

104 The occurrence and severity of peripheral neuropathy was assessed according to the  
105 guidelines of the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0,  
106 Published: November 27, 2017, by the U.S. Department of Health and Human Services  
107 ([https://ctep.cancer.gov/protocoldevelopment/electronic\\_applications/docs/ctcae\\_v5\\_quick\\_r](https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf)  
108 [eference\\_5x7.pdf](https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf)). Neuropathy assessment was performed prospectively, i.e., before the  
109 first paclitaxel treatment and again after the 12<sup>th</sup> treatment cycle. Neuropathy was assessed  
110 regularly upon visit of the patient. The last assessment was performed 4.5 years after initial  
111 chemotherapy (Table S1).

112 The severity of neuropathy was graded into five grades: Grade 1 Mild; asymptomatic or mild  
113 symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2  
114 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate  
115 instrumental ADL (activities of daily living). Grade 3 Severe or medically significant but not  
116 immediately life-threatening hospitalization or prolongation of hospitalization indicated;  
117 disabling; limiting self-care ADL. Grade 4 Life-threatening consequences; urgent intervention  
118 indicated. Grade 5 Death related to AE. In the present cohort, grades 1-3 were detected

119 following paclitaxel chemotherapy (Table S1). Of the 31 patients with a full set of samples, 17  
120 had neuropathy after chemotherapy (54.9%), 12 had grade 1, 3 had grade 2 and two patients  
121 with grade 3 (Table S1).

### 122 ***Lipidomics analysis using LC-MS/MS and LC-QTOFMS***

123 Blood was collected from patients in EDTA tubes and immediately centrifuged at 2000 xg for  
124 10 minutes at 4°C. The supernatant was immediately frozen at -80°C until further processing.  
125 Approximately 2-3 ml of plasma was considered sufficient for each patient. Liquid  
126 chromatography-tandem mass spectrometry (LC-MS/MS) analysis of eicosanoids, oxidized  
127 linoleic acid metabolites (O(x)LAMs), prostanoids, endocannabinoids, LPAs, pterins,  
128 sphingolipids and ceramides, and lipidomics screening were performed as described  
129 previously (13, 19, 21). A total of 255 lipids were quantified in each plasma sample. These  
130 lipids belong to the groups of eicosanoids, oxidized linoleic acid metabolites,  
131 endocannabinoids, lysophosphatidic acids, pterins, sphingolipids, ceramides, cholesterol,  
132 cholesterol esters, diacylglycerols, triacylglycerols, phospholipids, lysophospholipids, and  
133 free fatty acids. Full details of the lipids detected are given in Table S2. Full details of the LC-  
134 MS methods used can be found in the Supporting Information Methods section (Tables 1-  
135 10).

### 136 ***Data analysis***

137 The data analysis combined statistical and machine learning methods ("mixture of experts"  
138 approach) shown to be superior to relying on a single method (23)(24), such as regression  
139 analysis alone (22). The data analysis included unsupervised and supervised methods  
140 (**Figure 1**). Unsupervised methods were used to establish whether the lipidomics data  
141 contained structures that supported prior classification into (i) baseline and post-treatment  
142 samples, or (ii) subjects with or without neuropathy in the post-treatment samples.

143 Supervised methods were then used to identify lipid mediators that carried information  
144 relevant to the class structure of the data set. Programming was performed in R language  
145 (25) using the R software package (26), version 4.1.2, for Linux, available free of charge from  
146 the Comprehensive R Archive Network (CRAN) at <https://CRAN.R-project.org/>, and in  
147 Python language (27) using Python version 3.8.12, available free of charge at  
148 <https://www.python.org> (accessed March 1, 2022). The data analysis is summarized in  
149 Figure 1 and described in detail in the supporting information.

150 Following log-transformation and missing-value imputation, the lipid marker concentrations  
151 were analyzed using unsupervised methods to assess whether they contained structures that  
152 were consistent with the prior class structure. Z-standardized data were projected from the  
153 high-dimensional space onto lower dimensional planes by means of principal component  
154 analysis (PCA) (28, 29) as one of the classical methods established. As an alternative  
155 approach, unsupervised machine learning was implemented as self-organizing maps (SOM)  
156 of artificial neurons (30). In their special form of emergent SOM (ESOM (31)), the present  
157 map consisted of 4,000 neurons arranged on a two-dimensional toroidal grid with 50 rows  
158 and 80 columns (32, 33).

159 Supervised methods included binary logistic regression (36) and, since a mixture of experts  
160 was preferred (22-24), additional machine-learning algorithms of different types known to  
161 work well for tabular numerical data were applied. These included random forests (37, 38) as  
162 a robust tree-based bagging classifier, support vector machines (SVM) (39) as a hyperplane  
163 separation-based method. Classifier tuning is described in the supporting information. The  
164 analyses were performed using cross-validation and training, testing, and validation splits of  
165 the dataset as a machine learning standard. That is, a class-proportional random sample of  
166 20% of the dataset was set aside before the analyses started and served as a validation  
167 sample that was not touched during algorithm training and feature selection. In the remaining

168 80% of the dataset, feature selection was performed using supervised analyses in 100-fold  
169 nested cross-validation scenarios. Feature selection, i.e., identification of the individual lipid  
170 mediators that contained relevant information to assign a sample to either the pre- or post-  
171 therapy day or to a patient with or without neuropathy, was identified by majority vote among  
172 17 different feature selection methods, including univariate and multivariate types listed in the  
173 supporting information. After quantifying the importance of each feature, the most relevant  
174 subset of lipid mediators was identified by subjecting the importance measures to computed  
175 ABC analysis (cABC analysis) (40), an item categorization technique adopted from  
176 economics that aims to divide a set of positive numerical data into three disjoint subsets  
177 labeled "A," "B," and "C". The set "A" should contain the "few important" elements (41), which  
178 was retained. The resulting final sets of lipid mediators were then used to train the algorithms  
179 to perform the task of assigning a sample to either the pre- or post-therapy day or to a patient  
180 with or without neuropathy in the hold-out 20% validation sample mentioned above.

### 181 ***Calcium Imaging with primary sensory neurons***

182 Primary sensory neurons were cultured as described previously (42). For calcium imaging  
183 experiments, neurons were stained with Fura-2-AM (Thermo Fisher) for at least 60 min at  
184 37°C and washed afterwards twice with Ringer's solution consisting of 145 mM NaCl, 1.25  
185 mM  $\text{CaCl}_2 \times 2\text{H}_2\text{O}$ , 1 mM  $\text{MgCl}_2 \times 6 \text{H}_2\text{O}$ , 5 mM KCl, 10 mM D-glucose, and 10 mM HEPES  
186 adjusted to a pH of 7.3. To investigate the effect of SA1P or LPC 24:0 on different TRP  
187 channels, sensory neurons were incubated with the lipids for 1 min at a concentration of 1 or  
188 10  $\mu\text{M}$ , respectively. The gold standard agonists for TRPV1 and TRPA1 were capsaicin (200  
189 nM, 20s) and AITC (allyl isothiocyanate, 75  $\mu\text{M}$ , 30s). Fingolimod was used at a  
190 concentration of 1  $\mu\text{M}$  and pre-incubated for 1 h prior to measurement. As a positive control,  
191 final stimulation with KCl (50 mM, 1 min) was used to depolarize all neurons. All stimulating  
192 compounds were dissolved in Ringer's solution to their final concentrations.



193 The calcium imaging data were analyzed using descriptive statistics. All calcium imaging  
194 data are presented as the mean  $\pm$  SEM. Normal distribution was confirmed using the  
195 Shapiro-Wilk test. For experiments comparing only two groups, unpaired and  
196 heteroscedastic Student's t-tests were conducted following Welch's correction. When  
197 comparing more than two groups, one-way analysis of variance (ANOVA) was used, and for  
198 the comparison of more than three groups, two-way ANOVA was conducted. For all  
199 statistical analyses of the calcium imaging data, the software GraphPad Prism 9.5 was used.  
200 Statistical significance was set at p value < 0.05.

## 201 **Results**

202 All patients received paclitaxel as adjuvant or neoadjuvant therapy, without any other  
203 potentially neurotoxic substances. Of the 60 patients from our analysis cohort, two were  
204 excluded due to rescheduling of paclitaxel therapy. Blood samples were obtained from 31  
205 patients before and after chemotherapy. Twenty lipid marker variables had > 20% missing  
206 values. Following exclusion of these patients and variables and imputation, a data matrix for  
207 further analyses was obtained, sized 79  $\times$  255 (79 data set instances, samples, and 255  
208 different lipid mediators Figure 1). An overview of the distribution of the lipid marker data is  
209 shown in Figure S1. These included 48 samples drawn on day 1 before therapy and 31  
210 samples drawn on day 2 after 12 cycles of paclitaxel therapy. On day 2, n = 17 of the 31  
211 patients had symptoms of neuropathy (54.9%), which is in line with previous clinical reports  
212 on occurrence and severity of paclitaxel-induced neuropathy (43, 44). Most patients reported  
213 grade 1 neuropathy, although two patients experienced grade 3 neuropathy. Occurrence and  
214 degree of neuropathy were monitored 4.5 years after finishing chemotherapy. The  
215 neuropathy lasted for several months or, in many cases, still persisted for 4.5 years after  
216 chemotherapy at the last examination (Table S1).

217 ***Results of unsupervised analysis of structure in the lipidomics data supporting prior***  
218 ***knowledge***

219 An overview of the distribution of the lipid marker data is shown in Figure S1. PCA yielded  $d$   
220 = 28 components with eigenvalues  $> 1$ , which together explained 93.93% of the total  
221 variance in the lipid mediators (Figure 2). The  $d = 86$  lipid mediators that contributed most to  
222 the relevant PCs were identified based on the membership to category "A" in the cABC  
223 analysis of the weighted variable contributions to each PC (Figure S2). This was carried over  
224 as one of the several feature importance measures to the supervised analyses reported in  
225 the next chapter. On the emergent self-organizing map (ESOM, Figure 2a), a clear  
226 separation of two clusters was observed, which provided support that the lipid mediators  
227 contained a data structure contingent with the prior classification into pre- and posttherapy  
228 samples (Fisher's exact test:  $p = 0.01054$ , odds ratio: 3.572973 with 95% confidence interval  
229 1.28 - 10.52; Figure 2b). The separation of samples on the ESOM also corresponded, but to  
230 a lesser extent, with the occurrence of neuropathy observed at the time of the 2<sup>nd</sup> blood  
231 sample ( $p = 0.03279$ , odds ratio 0.16, 95% confidence interval 0.0137 - 1.022).

232 The results of the unsupervised analysis thus supported that the lipidomics data contained a  
233 structure contingent on a known prior classification. This supported the continuation of data  
234 analysis with supervised methods to determine which of the lipids carried relevant  
235 information to assign a probe to a particular prior class.

236 ***Results of supervised analyses identifying lipid mediators relevant to the class structure***

237 *Lipid mediators informative for assigning samples to before or after paclitaxel therapy*

238 Based on the majority vote of the different approaches to feature selection including PCA  
239 importance and further univariate and multivariate feature selection methods specified in the

240 supplementary information,  $d = 77$  lipid mediators were found to provide relevant information  
241 on whether a sample was collected before or after paclitaxel therapy (Figure S3). When  
242 statistical (logistic regression) and machine learning (random forests, support vector  
243 machines - SVM) algorithms were trained with this set of lipid mediators, the assignment of a  
244 sample to day 1 or 2 was well above the guessing level (Table 2). By contrast, when the  
245 training data were randomly permuted, the performance fell to a balanced accuracy of 0.5,  
246 i.e., guessing level, which established that the obtained class assignment in the non-  
247 permuted scenario had not been due to overfitting. In addition, by rerunning the cABC  
248 analysis on the mediators assigned to subset “A” in the first run (“recursive” cABC analysis  
249 (45)), the informative set of lipid mediators could be further reduced to  $d = 27$  (Table 1). With  
250 these mediators, SVM and random forest were still able to detect whether an instance of a  
251 lipidomics dataset was from before or after paclitaxel treatment at a balanced accuracy better  
252 than expected from guessing.

### 253 *Lipid mediators informative for assigning post-paclitaxel therapy samples to neuropathy*

254 The  $n = 31$  samples from day 2 were probably too small to detect whether a sample was  
255 from a patient with neuropathy. Although the median balanced accuracies for the three  
256 algorithms to detect neuropathy in new cases unseen during training were up to 0.75, while  
257 only the guess level of 0.5 was achieved when using permuted data for training, the 95% CI  
258 of the performance measures was not separated from guess level. Therefore, features were  
259 selected using univariate methods (Cohen’s  $d$ , FPR, FWE). The small set of lipid mediators  
260 emerging from all three methods as informative for neuropathy again included SA1P (see  
261 above), and in addition sphingomyelin 33:1, and sphingomyelin 43:1. The three mediators  
262 differed significantly between samples from neuropathy-positive and neuropathy-negative  
263 patients (Figure 3).

264 ***Biological in-vitro validation of the machine learning based results***

265 The results of the supervised analysis thus established a limited set of lipid mediators to be  
266 regulated in association with paclitaxel therapy or with its side effect of inducing neuropathy.  
267 The top hit was sphinganine-1-phosphate (SA1P), also known as dihydrosphingosine-1-  
268 phosphate (DH-S1P), providing a basis for in vitro validation of its biological effects in the  
269 present context of neuropathy.

270 Calcium imaging measurements were performed on primary sensory neurons obtained from  
271 the murine dorsal root ganglia. We stimulated the neurons with 1 and 10  $\mu$ M SA1P (ranked  
272 as the primary hit) or LPC 24:0 (ranked as one of the least relevant lipids by machine  
273 learning analysis). We observed that SA1P caused a direct calcium transient in  
274 approximately 11.7% of KCl-responsive sensory neurons (Figure 4a, b). However, LPC 24:0  
275 did not induce any notable activation of sensory neurons at concentration of 1 and 10  $\mu$ M  
276 (Figure S4a-c). To further characterize the SA1P-responding neurons, we investigated their  
277 responsiveness to agonists of the TRP channels TRPV1 (capsaicin) and TRPA1 (AITC, allyl  
278 isothiocyanate), both of which are hallmarks of subpopulations of primary sensory neurons  
279 (46). Stimulating SA1P-responsive neurons with capsaicin and AITC revealed that 73% of  
280 these neurons also responded to capsaicin and 25% of them responded to AITC, whereas  
281 only 9.6% responded to both stimuli. Neurons were identified as responders to KCl (50 mM,  
282 1 min; Figure 4c, d).

283 To identify the receptors or channels responsible for SA1P-mediated calcium transients in  
284 sensory neurons, the selective TRPV1 antagonist AMG9810 was used. Neurons were  
285 stimulated twice with SA1P (1  $\mu$ M, 1 min) and AMG9810 (1  $\mu$ M or vehicle) was added two  
286 minutes prior to the second SA1P stimulus. The second SA1P response was entirely  
287 abolished when the neurons were treated with AMG9810, but not with the vehicle (Figure 5a-

288 c). The potency of AMG9810 was validated using the same measurement protocol as before  
289 but with capsaicin (200 nM, 20s) instead of SA1P, which is the gold standard agonist of  
290 TRPV1. AMG9810 completely blocked the second capsaicin response (Figure 5d). The  
291 involvement of S1P-receptors previously suggested to be the receptors for SA1P (47), was  
292 evident by studying S1PR1 and S1PR3 as the most highly expressed S1P receptors in  
293 sensory neurons (48), which are also targets of the approved drug fingolimod. Sensory  
294 neurons were incubated with fingolimod or vehicle for one hour and stimulated the neurons  
295 with SA1P (Fig. 5e, f). Comparing fingolimod- and vehicle-treated neurons, we observed that  
296 the response intensity to SA1P was similar (Figure 5g), while the number of neurons  
297 responding to SA1P was significantly decreased after fingolimod treatment (Figure 5h).

## 298 **Discussion**

299 SA1P induced a direct calcium transient in sensory neurons dependent on sphingosine 1-  
300 phosphate receptors (S1PR) and the transient receptor potential vanilloid 1 (TRPV1)  
301 channel. The results suggest that lipids are altered during paclitaxel treatment and that  
302 alterations in sphingolipid metabolism may be critical for the development of paclitaxel-  
303 induced peripheral neuropathy in patients. The final ("sparse") set of lipids regulated between  
304 sampling days (before and after paclitaxel treatment) was enriched for sphingolipids.  
305 Specifically, sphingolipids were significantly overrepresented among the top hits of lipids  
306 regulated between sampling days (Fisher's exact test:  $p = 0.01$ ), i.e., while 46 of the original  
307 255 lipid mediators were sphingolipids (18%) (Table S2), 11 of the 27 members of the final  
308 sparse marker set (40.7%) belonged to the group of sphingolipids. The main pathway in  
309 which the top hits are involved is shown in Figure 6. With the top hits ("sparse" feature set),  
310 three different algorithms (logistic regression, random forests, support vector machines)  
311 could be trained to identify, in new cases, whether a blood sample was drawn before or after  
312 paclitaxel therapy with a median balanced accuracy of up to 90%. Furthermore, the

313 classification of patients with regard to neuropathy after paclitaxel treatment was reflected in  
314 lipidomics in another sphingolipid, i.e., dihydrosphingosine sphinganine-1-phosphate (SA1P),  
315 which was elevated in patients with neuropathy.

316 The results from an unbiased machine-learning-based analysis are in line with those of  
317 previous reports that had used classical statistics mainly. For example, S1P was elevated in  
318 the spinal cord of mice after bortezomib treatment and during bortezomib-induced  
319 neuropathic pain. Blocking S1P1 receptor S1P1R with fingolimod effectively reduced  
320 bortezomib-induced mechanical hypersensitivity in vivo (14). Interestingly, targeting the S1P-  
321 S1P1R-axis was also found to reduce paclitaxel-induced neuropathic pain in vivo in a  
322 preclinical study (49). Further agreements of the present results relate to previous preclinical  
323 reports highlighting the significance of the sphingolipid pathway in persistent and neuropathic  
324 pain states (14, 50, 51). In addition, the S1P signaling axis was observed to be relevant in  
325 neuropathy and chemotherapy-induced neuropathic pain, which led to the suggestion of  
326 targeting S1P receptors as a novel approach to ameliorate chemotherapy-induced  
327 neuropathy and neuropathic pain (49, 52-55). Taken together, present results from lipid  
328 screening and unbiased machine-learning approach point towards a significant contribution  
329 of sphingolipid signaling in paclitaxel-induced neuropathy in patients, mainly via sphinganine-  
330 1-phosphate and sphingomyelins 33:1 and 43:1.

331 Sphinganine is a key branching point in the sphingolipid pathway, where it can either be  
332 acylated to form dihydroceramides or phosphorylated to SA1P by sphingosine kinases (56).  
333 Accumulation of sphinganine has been previously associated with reduced activity of  
334 ceramide synthase CerS2 (57). Interestingly, low CerS2 expression is a hallmark of various  
335 tumors (58). It is conceivable that a subgroup of the patient cohort still exhibits low CerS2  
336 expression after paclitaxel treatment, which is associated with higher SA1P levels and a  
337 higher occurrence of neuropathy. We also identified SA1P as a potential proalgesic lipid

338 mediator, as it causes direct calcium transients in approximately 10% of sensory neurons.  
339 This effect is mediated, at least in part, by S1P receptors S1P1 and S1P3 and the TRPV1  
340 channel. The TRPV1 channel has previously been identified as an important mediator of  
341 neuropathic pain and is associated with exacerbated activity of sensory neurons during  
342 paclitaxel-induced neuropathic pain (59-61). Our data suggest that an S1P receptor  
343 modulator, such as fingolimod may be a potential treatment strategy for reducing the  
344 proalgesic effect of SA1P and possibly for reducing paclitaxel-induced neuropathy in  
345 patients.

346 Several other lipids were found in the extended list of hits previously associated with  
347 chemotherapy-induced neuropathy or acute pain in preclinical studies, such as LPC 18:1,  
348 sphingosin-1-phosphate (S1P), and 9,10-EpOME. LPC 18:1 has previously been identified  
349 as an endogenous activator of TRPV1 and TRM8 and was found at elevated levels in murine  
350 DRGs 24 h after oxaliplatin treatment. This may contribute to oxaliplatin-induced acute pain  
351 (62). Similarly, 9,10-EpOME was elevated in the DRGs of paclitaxel-treated mice. locking its  
352 synthesis with the CYP2J2-inhibitor and the approved drug telmisartan was shown to reduce  
353 acute paclitaxel-induced mechanical hypersensitivity in vivo and prevent paclitaxel-induced  
354 mechanical allodynia by pretreatment (13). In addition, the direct TRPV1 agonist LPA 18:1  
355 was found in the extended list of hits. Lipid was shown to bind to the C-terminal binding site  
356 of TRPV1 to increase the opening probability of the channel (63). Other signaling lipids with  
357 potential proalgesic effects and potential TRP channel activators that have been described  
358 previously have also been identified as crucial for group separation by our unbiased  
359 machine-learning approach, which strengthens the presumption that the identified lipids may  
360 indeed be connected with paclitaxel neurotoxicity and paclitaxel-induced neuropathy in  
361 patients. Additionally, we found several precursor fatty acids in the extended list of hits,  
362 including arachidonic acid, linoleic acid, and palmitic acid. These results imply a major

363 dysregulation of lipids after paclitaxel treatment, leading to enhanced plasma levels of  
364 precursors for eicosanoids and oxidized linoleic acid metabolites, which may explain the  
365 observed enhanced concentrations of the eicosanoids of 5-HETE, 5,6-DHET, and the  
366 oxidized linoleic acid metabolites 9,10-EpOME, 9- and 13-HODE.

367 Several limitations need to be addressed. First, the cohort size (n=60 patients, n=31 patients  
368 who provided blood samples before and after paclitaxel chemotherapy our patient cohort  
369 allowed for errors due to interindividual differences. Second, the paclitaxel treatment regimen  
370 differed in some patients included in this study. While the majority of the patients received  
371 paclitaxel as “pacli weekly” regime consisting of a weekly dose of 80 mg/m<sup>2</sup> for 12  
372 consecutive weeks in, some few patients received paclitaxel doses up to 220 mg/m<sup>2</sup> or a  
373 combination chemotherapy consisting of carboplatin/paclitaxel. These variabilities within the  
374 patient cohort hamper interindividual correlations between plasma lipid mediator  
375 concentrations and paclitaxel-induced neuropathy throughout the treatment course. Third,  
376 the assessment of peripheral neuropathy in patients was performed according to the  
377 guidelines of the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0,  
378 which ranks the severity of neuropathy into five grades but is rather focused on general  
379 adverse events of chemotherapy rather than specifically assessing peripheral neuropathy in  
380 detail. We did not perform any neurological testing of sensory parameters, such as  
381 quantitative sensory testing (QST) (64), to determine the sensory status quo of the patients.  
382 The study lacked a separate validation cohort with similar data to the main cohort. However,  
383 an independent second cohort was available from another hospital (Oncological Center in  
384 Offenbach, Germany). This cohort consisted of 28 patients treated with the "paclitaxel  
385 weekly" regimen (paclitaxel 80 mg/m<sup>2</sup>, once weekly) as adjuvant or neoadjuvant therapy for  
386 breast or ovarian cancer. All patients provided informed consent into study participation and  
387 publication of the results. Blood samples were available from routine collections and were



388 analyzed by LC-MS/MS (Figure S5, Table S3). In contrast to the main cohort, plasma from  
389 patients in the second cohort was collected after 6 cycles of paclitaxel treatment due to local  
390 routines. Therefore, the second cohort cannot be considered a state-of-the-art validation  
391 cohort. In addition, only six patients in this cohort had neuropathy after chemotherapy  
392 (26.5%), all with grade 1 neuropathy (Table S4). Despite these limitations, algorithms trained  
393 with lipid information from cohort 1 were able to successfully identify whether a probe was  
394 taken before or after paclitaxel therapy in the second cohort at a better than guessing level.  
395 Furthermore, a trend towards different SA1P concentrations in the plasma of patients after  
396 paclitaxel treatment was observed ( $p = 0.086$ , Figure 7).

## 397 **Conclusions**

398 Here, we demonstrate that the combination of state-of-the-art lipidomics using LC-MS/MS,  
399 LC-QTOF-MS, and machine learning-based data analysis can robustly lead to the generation  
400 of testable hypotheses and the identification of biologically relevant signaling mediators of  
401 neuropathy in an unbiased manner. Lipidomic profiles were compared within the same  
402 patients, allowing analysis of individual paclitaxel-induced lipidome changes in the same  
403 patients. These analyses led to the identification of a lipid mediator that can directly activate  
404 calcium transients in sensory neurons, thereby modulating nociceptive processing and  
405 sensory neuron activity. The identified SA1P, through its receptors, provides a potential drug  
406 target for co-therapy with paclitaxel to reduce one of its major and therapy-limiting side  
407 effects.

## 408 **Data availability**

409 Data are available on request from the senior author. Relevant Python and R code is  
410 available at <https://github.com/JornLotsch/PaclitaxelNeuropathyProject>.

## 411 **Author Contributions**

412 MS and GG conceptualized and designed the experiments. JL and SM performed the  
413 machine learning analysis. LH, CA, YS, ST, DT, and NFB performed lipidomics  
414 measurements and analyzed the data. SW and MS performed calcium imaging experiments.  
415 KG, CB, and CS assembled the patient cohorts. JL, KG, SW and MS wrote the manuscript.  
416 All authors have reviewed and edited the manuscript.

## 417 **Acknowledgments**


418 MS was supported by the Deutsche Forschungsgemeinschaft (German Research  
419 Foundation, DFG, Grants SFB1039 A09 and Z01) and from the Fraunhofer Foundation  
420 Project: Neuropathic Pain as well as the Fraunhofer Cluster of Excellence for Immune-  
421 Mediated Diseases (CIMD). This work was also supported by the Leistungszentrum  
422 Innovative Therapeutics (TheraNova) funded by the Fraunhofer Society and the Hessian  
423 Ministry of Science and Arts. JL was supported by the Deutsche Forschungsgemeinschaft  
424 (DFG LO 612/16-1). These public funders had no role in study design, data collection and  
425 analysis, decision to publish, or preparation of the manuscript. We would also like to thank  
426 Drs Tabea Osthues, Béla Zimmer and Vittoria Rimola, as well as Mr. Maksim Sendetski for  
427 their help in patient sample processing.

## 428 **Supplementary data captions**

429 Figure S1: Log<sub>10</sub>-transformed concentrations of the analyzed lipid mediators presented as  
430 violin plots showing the probability density distribution of the variables; Figure S2: Results of  
431 a projection of the z-standardized log-transformed lipidomics data onto a lower-dimensional  
432 space by means of PCA; Figure S3: Identification of the lipid mediators that were most  
433 informative in assigning a sample to the pre- or post-therapy time point. Feature selection by

434 13 different methods; Figure S4: Effects of Lysophosphatidylcholine 24:0 (LPC 24:0) on  
435 primary sensory neurons; Figure S5: Plasma lipids from the independent second patient  
436 cohort. Table S1: Patient characteristics of the 31 patients that gave blood samples before  
437 and after chemotherapy from the patient cohort; Table S2: Complete list of lipid mediators  
438 included in the analyses, separated by group of lipid and detection method; Table S3:  
439 External validation of the classifiers; Table S4: Patient characteristics of the 28 patients from  
440 the second cohort that gave blood samples before and after the sixth cycle of chemotherapy.  
441 Supplementary methods: data analysis, data preprocessing, supervised and unsupervised  
442 machine learning, lipid mediatorinformative for assigning samples to before or after therapy  
443 in an independent second patient cohort, lipidomics analyses of plasma patient samples  
444 (Tables 1-10).

445 **Figures and Tables**




446

447

448 **Figure 1: Flowchart showing the number of patients included and the workflow of the data**  
 449 **analysis.** UCT: University Cancer Center Frankfurt, PCA: principal component analysis, ESOM:  
 450 emergent self-organizing maps, cABC analysis: computed ABC analysis. The figure was created using  
 451 Microsoft PowerPoint® (Redmond, WA, USA) on Microsoft Windows 11 running in a virtual machine


452 powered by VirtualBox 6.1.36 (Oracle Corporation, Austin, TX, USA) as guest on Linux, and then  
453 further modified with the free vector graphics editor “Inkscape (version 1.2 for Linux,  
454 <https://inkscape.org/>



455

456

457 **Figure 2: Results of a projection of the z-standardized log-transformed lipidomics data onto a**  
458 **lower-dimensional space by means of a self-organizing map of artificial neurons (bottom). a):**  
459 Emergent self-organizing map (ESOM), providing a 3-dimensional U-matrix visualization of distance-  
460 based structures of the serum concentrations of  $d = 255$  lipid mediators following projection of the data  
461 points onto a toroid grid of 4,000 neurons where opposite edges are connected. The dots represent  
462 the so-called “best matching units” (BMU), i.e., neurons on the grid that after ESOM learning carried a  
463 data vector that was most similar to a data vector of a sample in the data set. Please note that one  
464 BMU can carry vectors of several cases, i.e., the number of BMUs is not necessarily equal to the  
465 number of cases. The U-matrix visualization was colored as a top view of a topographic map with  
466 brown (up to snow-covered) heights and green valleys with blue lakes. Watersheds indicate  
467 borderlines between two different regions (clusters) separated by the white “mountain ridge” at the left  
468 of the U-matrix. BMUs belonging to the two different clusters are colored in green or bluish. **b):** Mosaic  
469 plot of the prior classes (day 1 or day 2) versus the ESOM/Umatrix based clusters. The separation  
470 corresponded to the prior classification into pre- and posttherapy probes (day1/2). The figure has been  
471 created using the R software package (version 4.1.2 for Linux; <https://CRAN.R-project.org/> (26)) and  
472 the libraries “ggplot2” (<https://cran.r-project.org/package=ggplot2> (65)) and “Umatrix” ([https://cran.r-](https://cran.r-project.org/package=Umatrix)  
473 [project.org/package=Umatrix](https://cran.r-project.org/package=Umatrix) (31)).



474


475

476 **Figure 3: Log<sub>10</sub>-transformed concentrations of lipid mediators shown to be informative for assigning a post-therapy sample to a patient with**  
 477 **neuropathy or a patient without neuropathy.** Individual data points are presented as dots on violin plots showing the probability density distribution of the

478 variables, overlaid with box plots where the boxes were constructed using the minimum, quartiles, median (solid line inside the box) and maximum of these  
479 values. The whiskers add 1.5 times the interquartile range (IQR) to the 75<sup>th</sup> percentile or subtract 1.5 times the IQR from the 25<sup>th</sup> percentile. **a)**: Concentrations of  
480 SA1P (top hit for sample 1 versus sample 2 segregation) are presented separately for the first and second samples. **b)**: Concentrations of the top lipid mediators  
481 for neuropathy versus no neuropathy in the second sample presented separately for neuropathy-positive and -negative samples. The results of the group  
482 comparison statistics are given at the top of the graphs. The figure has been created using the R software package (version 4.1.2 for Linux; [http://CRAN.R-](http://CRAN.R-project.org/)  
483 [project.org/](http://CRAN.R-project.org/) (26)) and the R library "ggplot2" (<https://cran.r-project.org/package=ggplot2> (65)).



484




485

486 **Figure 4: Effects of sphinganine-1-phosphate on primary sensory neurons.** a) Neurons  
 487 were stimulated with SA1P (1 or 10 μM, 1min or vehicle (0.7% methanol (v/v)). b) percentage of  
 488 responding neurons to vehicle (0.7% methanol (v/v), 1 min), (SA1P (1 μM, 1min), AITC (allyl  
 489 isothiocyanate, 75 μM, 30s) or capsaicin (caps, 200 nM, 20s). c) representative traces of SA1P-  
 490 responding neurons and their response to AITC, capsaicin and KCl. d) percentage of SA1P-  
 491 responding neurons responding to AITC, capsaicin (caps), AITC and capsaicin and KCl. Data are  
 492 shown as mean ± SEM from at least six measurements per condition with at least 40 neurons per  
 493 measurement, \* p < 0.05, \*\* p < 0.01, \*\*\* p < 0.01, One-way ANOVA

494

495



496


497 **Figure 5: Contribution of TRPV1 and S1P receptors to SA1P-mediated calcium-influx in**  
 498 **sensory neurons.** Sensory neurons were stimulated with SA1P twice (1  $\mu$ M, 1 min) and either **a)**

499 vehicle (DMSO 0.003% (v/v), 2 min) or **b)** the TRPV1 antagonist AMG9810 (1  $\mu$ M, 2 min) prior to  
500 the second SA1P stimulus. Cells were depolarized with KCl (50 mM, 1 min) at the end of each  
501 experiment. **c)** Statistical analysis of the amplitude of SA1P-mediated calcium transients in  
502 sensory neurons treated with either vehicle or AMG9810 (blue). **d)** Statistical analysis of the  
503 amplitude of capsaicin-mediated calcium transients (100 nM, 20s) in sensory neurons treated  
504 with either vehicle or AMG9810 (blue). **e), f)** Sensory neurons were stimulated with SA1P after  
505 preincubation with the S1P1 receptor modulator fingolimod (1  $\mu$ M, 1 h) or control. **g)** Statistical  
506 analysis of the amplitude of SA1P-mediated calcium transients (1  $\mu$ M, 1min) in sensory neurons  
507 treated with either vehicle or fingolimod (1  $\mu$ M, 1h, orange). **h)** Statistical analysis of the number  
508 of SA1P-responding neurons (as % of KCl-positives) after treatment with either vehicle or  
509 fingolimod (1  $\mu$ M, 1h, orange). Data represents mean  $\pm$  SEM from at least five measurements per  
510 condition with at least 25 neurons per measurement, \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.01$ ,  
511 Student's t-test with Welch's correction.

512

513


514



515 **Sphingomyelin**

516

517 **Figure 6: Sphingolipids and Ceramides** (SPT: Serine palmitoyl-transferase; 3KR: 3-  
 518 ketosphinganine reductase; SPHK: Sphingosine kinase; CerS: Ceramide synthase; DEGS:  
 519 Dihydroceramide desaturase, GICerS: Glucosylceramide synthase; LacCerS: Lactosylceramide  
 520 synthase; SMS: Sphingomyelin synthase; CDase: Ceramidase). Structures were drawn with  
 521 ChemDraw 20.



522

523

524 **Figure 7: Log10-transformed concentrations of SA1P in the second patient cohort.**

525 Individual data points are presented as dots on violin plots showing the probability density

526 distribution of the variables, overlaid with box plots where the boxes were constructed using the

527 minimum, quartiles, median (solid line inside the box) and maximum of these values. The

528 whiskers add 1.5 times the interquartile range (IQR) to the 75th percentile or subtract 1.5 times

529 the IQR from the 25th percentile. a): Concentrations of SA1P (top hit for sample 1 versus sample

530 2 segregation) are presented separately for the first and second samples. b): Concentrations of

531 S1AP in the second sample are shown separately for neuropathy-positive and -negative samples.

532 Day 1 represents the timepoint before starting chemotherapy. Day 2 represents the timepoint

533 after 12 cycles of paclitaxel chemotherapy. The results of the t-test group comparison statistics

534 are given at the top of the graphs. The figure has been created using the R software package

535 (version 4.1.2 for Linux; <http://CRAN.R-project.org/> (**26**)) and the R library "ggplot2" ([https://cran.r-](https://cran.r-project.org/package=ggplot2)  
536 [project.org/package=ggplot2](https://cran.r-project.org/package=ggplot2) (**65**)).

537

538 **Table 1: Lists of lipid mediators that were most informative in assigning a sample (i) to the**  
 539 **first or second sampling time point or (ii) a sample from the second time point to a patient**  
 540 **with or without neuropathy.** Abbreviations: SA1P: sphinganine-1-phosphate, S1P: sphingosine-  
 541 1-phosphate, LPE: lysophosphatidylethanolamine, LPC: lysophosphatidylcholine, 2-AG: 2-  
 542 arachidonoylglycerol, OEA. Oleoylethanolamide.

<b>Sample 1 versus sample 2</b>				
<b>SA1P</b>	Sphingomyelin 42:1	Palmitic acid 16:0	Eicosaeinoic acid 20:1	PE 38:5
<b>LacCeramid C16</b>	LPE 22:6	Margaritic acid 17:0	2-AG	LPC 22:4
<b>S1P</b>	LPE 18:0p	Sphingomyelin 42:3	OEA	Cholesterolsulfa te
<b>Sphingomyelin 36:3</b>	LPE 18:0	LPC 18:0	Sphingomyelin 40:1	
<b>Ceramide 18:0</b>	LPC 20:1	LPC 18:1	Sphingomyelin 42:2	
<b>Ceramide 24:0</b>	Nervoneic acid 24:1	Dehydroepiandrosterone sulfate		
<b>Sample 2: neuropathy versus no neuropathy</b>				
<b>SA1P</b>	Sphingomyelin 33:1	Sphingomyelin 43:1		

543



544 **Table 2: Internal validation of the sets of lipid mediators resulting from the feature**  
 545 **selection analysis.** The different classifiers (linear support vector machine, SVM, random  
 546 forests, and logistic regression) were trained with subsets of the training data set with all variables  
 547 ( $d = 255$  lipid mediators as “full” feature set and with the  $d = 77$  or  $d = 27$  lipid mediators that had  
 548 resulted from the recursive cABC analysis applied on the sum score of selections by 17 different  
 549 feature selection methods as “reduced” or “sparse” feature sets, respectively. The trained  
 550 classifiers were applied to a validation sample comprising 20% of the data that had been  
 551 removed in a class-proportional manner from the dataset at the beginning of feature selection and  
 552 had not been touched until used in the classifier validation task presented in this table. In  
 553 addition, the validation task was repeated with training the classifiers with permuted lipid  
 554 mediators to observe possible overfitting. Shown are the medians and nonparametric 95%  
 555 confidence intervals (2.5<sup>th</sup> to 97.5<sup>th</sup> percentiles) from 5 x 20 nested cross-validation runs. Results  
 556 of external validation in an independent cohort are shown in the supporting information (Table  
 557 S3).

Classifier	Performance measure	Feature set			
		Full	Reduced	Reduced permuted	Sparse
	<b>Number of lipid mediators</b>	255	77	77	27
<b>SVM</b>	Balanced accuracy	0.7 (0.48 - 0.92)	0.78 (0.61 - 1)	0.48 (0.23 - 0.76)	0.75 (0.54 - 0.91)
<b>Random forests</b>		0.7 (0.56 - 0.83)	0.75 (0.58 - 0.85)	0.46 (0.24 - 0.75)	0.74 (0.55 - 0.88)

<b>Logistic regression</b>		0.7 (0.52 - 0.85)	0.77 (0.58 - 0.92)	0.48 (0.29 - 0.7)	0.7 (0.49 - 0.89)
<b>SVM</b>	roc-auc	0.88 (0.67 - 1)	0.95 (0.85 - 1)	0.48 (0.16 - 0.77)	0.9 (0.81 - 0.99)
<b>Random forests</b>		0.86 (0.76 - 0.95)	0.88 (0.81 - 0.98)	0.48 (0.21 - 0.81)	0.9 (0.8 - 1)
<b>Logistic regression</b>		0.81 (0.64 - 1)	0.88 (0.75 - 1)	0.46 (0.16 - 0.79)	0.86 (0.69 - 0.98)

558

559

## 560 References

- 561 1. Pachman DR, Barton DL, Watson JC, and Loprinzi CL. Chemotherapy-induced peripheral  
562 neuropathy: prevention and treatment. *Clin Pharmacol Ther.* 2011;90(3):377-87.
- 563 2. Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, et al.  
564 Chemotherapy-induced peripheral neurotoxicity: a critical analysis. *CA: a cancer journal*  
565 *for clinicians.* 2013;63(6):419-37.
- 566 3. Cavaletti G, and Marmiroli P. Management of Oxaliplatin-Induced Peripheral Sensory  
567 Neuropathy. *Cancers (Basel).* 2020;12(6).
- 568 4. Smith EML, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al. Effect of  
569 Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-  
570 Induced Painful Peripheral Neuropathy A Randomized Clinical Trial. *Jama-J Am Med*  
571 *Assoc.* 2013;309(13):1359-67.
- 572 5. Gornstein E, and Schwarz TL. The paradox of paclitaxel neurotoxicity: Mechanisms and  
573 unanswered questions. *Neuropharmacology.* 2014;76 Pt A:175-83.
- 574 6. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al.  
575 Prevention and management of chemotherapy-induced peripheral neuropathy in  
576 survivors of adult cancers: American Society of Clinical Oncology clinical practice  
577 guideline. *J Clin Oncol.* 2014;32(18):1941-67.
- 578 7. Yang CH, and Horwitz SB. Taxol((R)): The First Microtubule Stabilizing Agent. *Int J Mol*  
579 *Sci.* 2017;18(8).
- 580 8. Diaz PL, Furfari A, Wan BA, Lam H, Charames G, Drost L, et al. Predictive biomarkers of  
581 chemotherapy-induced peripheral neuropathy: a review. *Biomark Med.* 2018;12(8):907-  
582 16.
- 583 9. Sisignano M, Lotsch J, Parnham MJ, and Geisslinger G. Potential biomarkers for  
584 persistent and neuropathic pain therapy. *Pharmacol Ther.* 2019;199:16-29.
- 585 10. Huehnchen P, Schinke C, Bangemann N, Dordevic AD, Kern J, Maierhof SK, et al.  
586 Neurofilament proteins as a potential biomarker in chemotherapy-induced  
587 polyneuropathy. *Jci Insight.* 2022;7(6).
- 588 11. Hohmann SW, Angioni C, Tunaru S, Lee S, Woolf CJ, Offermanns S, et al. The G2A  
589 receptor (GPR132) contributes to oxaliplatin-induced mechanical pain hypersensitivity.  
590 *Sci Rep.* 2017;7(1):446.

- 591 12. Piomelli D, and Sasso O. Peripheral gating of pain signals by endogenous lipid mediators.  
592 *Nat Neurosci.* 2014;17(2):164-74.
- 593 13. Sisignano M, Angioni C, Park CK, Meyer Dos Santos S, Jordan H, Kuzikov M, et al.  
594 Targeting CYP2J to reduce paclitaxel-induced peripheral neuropathic pain. *Proc Natl*  
595 *Acad Sci U S A.* 2016;113(44):12544-9.
- 596 14. Stockstill K, Doyle TM, Yan X, Chen Z, Janes K, Little JW, et al. Dysregulation of  
597 sphingolipid metabolism contributes to bortezomib-induced neuropathic pain. *J Exp*  
598 *Med.* 2018;215(5):1301-13.
- 599 15. Gonzalez De Aguilar JL. Lipid Biomarkers for Amyotrophic Lateral Sclerosis. *Front Neurol.*  
600 2019;10:284.
- 601 16. Trostchansky A. Overview of Lipid Biomarkers in Amyotrophic Lateral Sclerosis (ALS).  
602 *Adv Exp Med Biol.* 2019;1161:233-41.
- 603 17. Zarrouk A, Debbabi M, Bezine M, Karym EM, Badreddine A, Rouaud O, et al. Lipid  
604 Biomarkers in Alzheimer's Disease. *Curr Alzheimer Res.* 2018;15(4):303-12.
- 605 18. Osthues T, and Sisignano M. Oxidized Lipids in Persistent Pain States. *Front Pharmacol.*  
606 2019;10:1147.
- 607 19. Shapiro H, Singer P, and Ariel A. Beyond the classic eicosanoids: Peripherally-acting  
608 oxygenated metabolites of polyunsaturated fatty acids mediate pain associated with  
609 tissue injury and inflammation. *Prostaglandins Leukot Essent Fatty Acids.* 2016;111:45-  
610 61.
- 611 20. Sisignano M, Bennett DL, Geisslinger G, and Scholich K. TRP-channels as key integrators  
612 of lipid pathways in nociceptive neurons. *Prog Lipid Res.* 2014;53:93-107.
- 613 21. Brunkhorst-Kanaan N, Klatt-Schreiner K, Hackel J, Schroter K, Trautmann S, Hahnefeld L,  
614 et al. Targeted lipidomics reveal derangement of ceramides in major depression and  
615 bipolar disorder. *Metabolism.* 2019;95:65-76.
- 616 22. Leclercq M, Vittrant B, Martin-Magniette ML, Scott Boyer MP, Perin O, Bergeron A, et al.  
617 Large-Scale Automatic Feature Selection for Biomarker Discovery in High-Dimensional  
618 OMICs Data. *Front Genet.* 2019;10:452.
- 619 23. Khadirnaikar S, Shukla S, and Prasanna SRM. Machine learning based combination of  
620 multi-omics data for subgroup identification in non-small cell lung cancer. *Sci Rep.*  
621 2023;13(1):4636.

- 622 24. Hu YH, Palreddy S, and Tompkins WJ. A patient-adaptable ECG beat classifier using a  
623 mixture of experts approach. *IEEE Trans Biomed Eng.* 1997;44(9):891-900.
- 624 25. Ihaka R, and Gentleman R. R: A Language for Data Analysis and Graphics. *Journal of*  
625 *Computational and Graphical Statistics.* 1996;5(3):299-314.
- 626 26. R Development Core Team. R: A Language and Environment for Statistical Computing.  
627 2008.
- 628 27. Van Rossum G, and Drake Jr FL. *Python tutorial.* Centrum voor Wiskunde en Informatica  
629 Amsterdam; 1995.
- 630 28. Hotelling H. Analysis of a complex of statistical variables into principal components.  
631 *Journal of Educational Psychology.* 1933;24(7):498-520.
- 632 29. Pearson K. LIII. On lines and planes of closest fit to systems of points in space. *The*  
633 *London, Edinburgh, and Dublin Philosophical Magazine and Journal of Science.*  
634 1901;2(11):559-72.
- 635 30. Kohonen T. Self-organized formation of topologically correct feature maps. *Biol*  
636 *Cybernet.* 1982;43:59-69.
- 637 31. Lötsch J, Lerch F, Djaldetti R, Tegeder I, and Ultsch A. Identification of disease-distinct  
638 complex biomarker patterns by means of unsupervised machine-learning using an  
639 interactive R toolbox (Umatrix). *BMC Big Data Analytics.*  
640 2018;3(5):<https://doi.org/10.1186/s41044-018-0032-1>.
- 641 32. Ultsch A. Maps for Visualization of High-Dimensional Data Spaces. *WSOM.* 2003:225-30.
- 642 33. Ultsch A, and Lötsch J. Machine-learned cluster identification in high-dimensional data. *J*  
643 *Biomed Inform.* 2017;66:95-104.
- 644 34. Ultsch A, and Sieman HP. *INNC'90, Int Neural Network Conference.* Dordrecht,  
645 Netherlands: Kluwer; 1990:305-8.
- 646 35. Lötsch J, and Ultsch A. In: Villmann T, Schleif F-M, Kaden M, and Lange M eds. *Advances*  
647 *in Intelligent Systems and Computing.* Heidelberg: Springer; 2014:248-57.
- 648 36. Cramer JS. The Origins of Logistic Regression. 2002.
- 649 37. Ho TK. *Proceedings of the Third International Conference on Document Analysis and*  
650 *Recognition (Volume 1) - Volume 1.* IEEE Computer Society; 1995:278.
- 651 38. Breiman L. Random Forests. *Mach Learn.* 2001;45(1):5-32.

- 652 39. Cortes C, and Vapnik V. Support-Vector Networks. *Machine Learning*. 1995;20(3):273-  
653 97.
- 654 40. Ultsch A, and Lötsch J. Computed ABC Analysis for Rational Selection of Most  
655 Informative Variables in Multivariate Data. *PLoS One*. 2015;10(6):e0129767.
- 656 41. Juran JM. The non-Pareto principle; Mea culpa. *Quality Progress*. 1975;8(5):8-9.
- 657 42. Sisignano M, Park CK, Angioni C, Zhang DD, von Hehn C, Cobos EJ, et al. 5,6-EET Is  
658 Released upon Neuronal Activity and Induces Mechanical Pain Hypersensitivity via  
659 TRPA1 on Central Afferent Terminals. *The Journal of neuroscience : the official journal of  
660 the Society for Neuroscience*. 2012;32(18):6364-72.
- 661 43. Pachman DR, Barton DL, Watson JC, and Loprinzi CL. Chemotherapy-induced peripheral  
662 neuropathy: prevention and treatment. *Clin Pharmacol Ther*. 2011;90(3):377-87.
- 663 44. Scripture CD, Figg WD, and Sparreboom A. Peripheral neuropathy induced by paclitaxel:  
664 recent insights and future perspectives. *Curr Neuropharmacol*. 2006;4(2):165-72.
- 665 45. Lötsch J, and Ultsch A. Recursive computed ABC (cABC) analysis as a precise method for  
666 reducing machine learning based feature sets to their minimum informative size. *Sci  
667 Rep*. 2023;13(1):5470.
- 668 46. Julius D. TRP Channels and Pain. *Annu Rev Cell Dev Biol*. 2013;29:355-84.
- 669 47. Magaye RR, Savira F, Hua Y, Kelly DJ, Reid C, Flynn B, et al. The role of  
670 dihydrosphingolipids in disease. *Cell Mol Life Sci*. 2019;76(6):1107-34.
- 671 48. Quarta S, Camprubi-Robles M, Schweigreiter R, Matusica D, Haberberger RV, Proia RL, et  
672 al. Sphingosine-1-Phosphate and the S1P3 Receptor Initiate Neuronal Retraction via  
673 RhoA/ROCK Associated with CRMP2 Phosphorylation. *Front Mol Neurosci*. 2017;10:317.
- 674 49. Janes K, Little JW, Li C, Bryant L, Chen C, Chen Z, et al. The Development and  
675 Maintenance of Paclitaxel-induced Neuropathic Pain Require Activation of the  
676 Sphingosine 1-Phosphate Receptor Subtype 1. *J Biol Chem*. 2014;289(30):21082-97.
- 677 50. Squillace S, Spiegel S, and Salvemini D. Targeting the Sphingosine-1-Phosphate Axis for  
678 Developing Non-narcotic Pain Therapeutics. *Trends Pharmacol Sci*. 2020;41(11):851-67.
- 679 51. Chen Z, Doyle TM, Luongo L, Largent-Milnes TM, Giancotti LA, Kolar G, et al.  
680 Sphingosine-1-phosphate receptor 1 activation in astrocytes contributes to neuropathic  
681 pain. *Proc Natl Acad Sci U S A*. 2019.

- 682 52. Wang W, Xiang P, Chew WS, Torta F, Bandla A, Lopez V, et al. Activation of sphingosine  
683 1-phosphate receptor 2 attenuates chemotherapy-induced neuropathy. *J Biol Chem.*  
684 2020;295(4):1143-52.
- 685 53. Salvemini D, Doyle T, Kress M, and Nicol G. Therapeutic targeting of the ceramide-to-  
686 sphingosine 1-phosphate pathway in pain. *Trends Pharmacol Sci.* 2013;34(2):110-8.
- 687 54. Becker KA, Uerschels AK, Goins L, Doolen S, McQuerry KJ, Bielawski J, et al. Role of 1-  
688 Deoxysphingolipids in docetaxel neurotoxicity. *J Neurochem.* 2020;154(6):662-72.
- 689 55. Chua KC, Xiong C, Ho C, Mushiroda T, Jiang C, Mulkey F, et al. Genomewide Meta-  
690 Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory  
691 Peripheral Neuropathy. *Clin Pharmacol Ther.* 2020;108(3):625-34.
- 692 56. Merrill AH, Jr. Sphingolipid and glycosphingolipid metabolic pathways in the era of  
693 sphingolipidomics. *Chem Rev.* 2011;111(10):6387-422.
- 694 57. Pewzner-Jung Y, Brenner O, Braun S, Laviad EL, Ben-Dor S, Feldmesser E, et al. A critical  
695 role for ceramide synthase 2 in liver homeostasis: II. insights into molecular changes  
696 leading to hepatopathy. *J Biol Chem.* 2010;285(14):10911-23.
- 697 58. Zhang Q, Wang JY, Yan W, Wang DD, Yang SJ, Zhou SY, et al. Clinical and pathological  
698 significance of Homo sapiens ceramide synthase 2 (CerS-2) in diverse human cancers.  
699 *Biosci Rep.* 2019;39(5).
- 700 59. Jardin I, Lopez JJ, Diez R, Sanchez-Collado J, Cantonero C, Albarran L, et al. TRPs in Pain  
701 Sensation. *Front Physiol.* 2017;8:392.
- 702 60. Hara T, Chiba T, Abe K, Makabe A, Ikeno S, Kawakami K, et al. Effect of paclitaxel on  
703 transient receptor potential vanilloid 1 in rat dorsal root ganglion. *Pain.*  
704 2013;154(6):882-9.
- 705 61. Kamata Y, Kambe T, Chiba T, Yamamoto K, Kawakami K, Abe K, et al. Paclitaxel Induces  
706 Upregulation of Transient Receptor Potential Vanilloid 1 Expression in the Rat Spinal  
707 Cord. *Int J Mol Sci.* 2020;21(12).
- 708 62. Rimola V, Hahnefeld L, Zhao J, Jiang C, Angioni C, Schreiber Y, et al. Lysophospholipids  
709 Contribute to Oxaliplatin-Induced Acute Peripheral Pain. *J Neurosci.* 2020;40(49):9519-  
710 32.
- 711 63. Nieto-Posadas A, Picazo-Juarez G, Llorente I, Jara-Oseguera A, Morales-Lazaro S,  
712 Escalante-Alcalde D, et al. Lysophosphatidic acid directly activates TRPV1 through a C-  
713 terminal binding site. *Nat Chem Biol.* 2011.

- 714 64. Maier C, Baron R, Tolle TR, Binder A, Birbaumer N, Birklein F, et al. Quantitative sensory  
715 testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory  
716 abnormalities in 1236 patients with different neuropathic pain syndromes. *Pain*.  
717 2010;150(3):439-50.
- 718 65. Wickham H. *ggplot2: Elegant Graphics for Data Analysis*. Springer-Verlag New York;  
719 2009.
- 720